A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders, Alexander J. Bankovich, Wade C. Anderson et al. · Science Translational Medicine · 2015
The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX tumors and confirmed in primary SCLC and LCNEC tumors. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjugate (ADC), SC16LD6.5, comprised of a humanized anti-DLL3 monoclonal antibody conjugated to a DNA-damaging pyrrolobenzodiazepine (PBD) dimer toxin, induced durable tumor regression in vivo across multiple PDX models. Serial transplantation experiments executed with limiting dilutions of cells provided functional evidence confirming that the lack of tumor recurrence after SC16LD6.5 exposure resulted from effective targeting of DLL3-expressing TICs. In vivo efficacy correlated with DLL3 expression, and responses were observed in PDX models initiated from patients with both limited and extensive-stage disease and were independent of their sensitivity to standard-of-care chemotherapy regimens. SC16LD6.5 effectively targets and eradicates DLL3-expressing TICs in SCLC and LCNEC PDX tumors and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.
Cited by 600 works. doi:10.1126/scitranslmed.aac9459
Authors
- Laura R. Saunders
- Alexander J. Bankovich
- Wade C. Anderson
- Monette A. Aujay
- Sheila Bheddah
- KristenAnn Black
- Radhika C. Desai
- Paul A. Escarpe
- Johannes Hampl
- Amy Laysang
- Javier Lopez-Molina
- Milly Milton
- Marybeth A. Pysz
- Brian C. Slingerland
- Michael Y. Torgov
- Samuel A. Williams
- Orit Foord
References
- A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- Molecular interactions between the protein products of the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila
- Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
- Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo
- A Genomics-Based Classification of Human Lung Tumors
- Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
- An achaete-scute homologue essential for neuroendocrine differentiation in the lung
- Lineage dependency and lineage-survival oncogenes in human cancer